The proposed changes are not in line with current literature that supports access to care to treat the disease of obesity. Making changes that are discriminating toward patients who are affected by the disease of obesity and therefore restricts access to care to medical treatment.  This is not keeping with current medical Scientific base guidelines or FDA guidelines are indications for pharmacotherapy.  The medical and financial costs to delaying therapy should also be considered when making such policy decisions.